Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
NCT ID: NCT00289991
Last Updated: 2015-11-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
489 participants
INTERVENTIONAL
2006-03-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Itraconazole
Itraconazole
Prophylaxis
Voriconazole
Vfend - voriconazole
Prophylaxis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Itraconazole
Prophylaxis
Vfend - voriconazole
Prophylaxis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and Female over 12 years or greater
Exclusion Criteria
* Previous history of zygomycosis
* Anticipated survival less than one month
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Bmo, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Cairo, , Egypt
Pfizer Investigational Site
Marseille, Cedex 09, France
Pfizer Investigational Site
Caen, , France
Pfizer Investigational Site
Créteil, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Pessac, , France
Pfizer Investigational Site
Rouen, , France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, , France
Pfizer Investigational Site
Villejuif, , France
Pfizer Investigational Site
Exohi Asvestohoriou, Thessaloniki, Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Amman, , Jordan
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Badalona, Barcelona, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Salamanca, Salamanca, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Ch-4031 Basel, , Switzerland
Pfizer Investigational Site
Geneva, , Switzerland
Pfizer Investigational Site
Ankara, , Turkey (Türkiye)
Pfizer Investigational Site
Kayseri, , Turkey (Türkiye)
Pfizer Investigational Site
Sutton, Surrey, United Kingdom
Pfizer Investigational Site
Bristol, , United Kingdom
Pfizer Investigational Site
Cambridge, , United Kingdom
Pfizer Investigational Site
Cardiff, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Leeds, , United Kingdom
Pfizer Investigational Site
Leicester, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1501073
Identifier Type: -
Identifier Source: org_study_id